Study Title

blueearthdiagnosticsandtherapeutics

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

Study Details

Description:

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Sponsor:

Blue Earth Diagnostics and Therapeutics

Contacts:

Blue Earth Therapeutics

contact@blueearthtx.com

+44 (0)1865 634500

Government Study Link:

NCT05413850 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

XCancer - Omaha

17607 Gold Plaza, Omaha, Nebraska 68130, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Washington University School of Medicine

St. Louis, Missouri, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Weill Cornell Medicine at New York - Presbyterian

New York, New York 10021, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.


Cedars-Sinai Medical Center

Los Angeles, California, United States


Netherlands

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.